Targeting Inflammatory Pathways in Cardiovascular Disease: The Inflammasome, Interleukin-1, Interleukin-6 and Beyond.

摘要: Recent clinical trials have now firmly established that inflammation participates causally in human atherosclerosis. These observations point the way toward novel treatments add to therapies help stem growing global epidemic of cardiovascular disease. Fortunately, we a number actionable targets whose exploration will achieve goal optimizing beneficial effects while avoiding undue interference with host defenses or other unwanted actions. This review aims furnish foundation for this quest by critical evaluation current state anti-inflammatory interventions within close reach application, primary focus on innate immunity. In particular, paper highlights pathway from inflammasome, through interleukin (IL)-1 IL-6 supported promising body pre-clinical, clinical, and genetic data. also considers use biomarkers guide allocation as step realizing promise precision medicine. The validation decades experimental work association studies humans recent investigations provides strong impetus further efforts target atherosclerosis address considerable risk remains despite therapies.